# A Study of the Safety and Pharmacokinetics of rhGAA in Siblings With Glycogen Storage Disease Type II

> **NCT00051935** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 2 (actual)

## Conditions studied

- Glycogen Storage Disease Type II
- Pompe Disease
- Acid Maltase Deficiency Disease
- Glycogenosis 2

## Interventions

- **DRUG:** Alglucosidase alfa

## Key facts

- **NCT ID:** NCT00051935
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-01
- **Primary completion:** 2003-04
- **Final completion:** 2003-10
- **Target enrollment:** 2 (ACTUAL)
- **Last updated:** 2014-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00051935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00051935, "A Study of the Safety and Pharmacokinetics of rhGAA in Siblings With Glycogen Storage Disease Type II". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00051935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*